Immunogenicity in the past year we have succeeded in identifying the major B cell epitopes recognized by the human immune system and have made a new immunotoxin, HA22-LR-010, that is highly active and whose reactivity with human anti-sera is greatly reduced. We are trying to further decrease reactivity by making further mutations in the new immunotoxin. We have also initiated a program to identify and remove human specific T cell epitopes. We have now identified all the major T cell epitopes in the toxin and using alanine scanning mutagenisis identified which amino acids within the epitope can be mutated to silence the epitope and maintain high cytotoxic activity. Using this information we have made 2 new types of recombinant immunotoxins. One of these has all the major T cell epitopes silenced. The other has a combination of mutations that remove B and T cell epitopes. These new RITs are now being tested in mice with human tumor xenographs. Based on our ability to remove B cell epitopes, Roche has produced a new immunotoxin targeting mesothelin which is now in preclinical development. In collaboration with David FitzGerald we have begun to study how protein synthesis arrest leads to apoptosis and have identified BAK, Bax, MCL-1 and BCL-XL as critical players in this process. We are also studying how protein phosphorylation regulates sensitivity of cells to immunotoxin mediated cell death by doing knock down studies of tyrosine and serine/threonine kinases and measuring the effect of knock down of these kinases on immunotoxin mediated cell death. We have identified the insulin receptor, HCK, BMX and the PDGF beta receptor as kinases that regulate immunotoxin killing. Lowing levels of these proteins enhances immunotoxin action. We have also identified several TK inhibitors that enhance immunotoxin action against cultured tumors cells and tumors growing in mice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC008753-31
Application #
8763020
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
31
Fiscal Year
2013
Total Cost
$2,243,727
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Yamada, Sachiko; Nakamura, Jin; Asada, Misako et al. (2014) Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury. PLoS One 9:e89135
Matsusaka, Taiji; Niimura, Fumio; Pastan, Ira et al. (2014) Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. Kidney Int 85:1068-77
Denton, Paul W; Long, Julie M; Wietgrefe, Stephen W et al. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10:e1003872
Miyazaki, Yoichi; Shimizu, Akihiro; Ichikawa, Iekuni et al. (2014) Mice are unable to endogenously regenerate podocytes during the repair of immunotoxin-induced glomerular injury. Nephrol Dial Transplant 29:1005-12
Miyazaki, Yoichi; Shimizu, Akihiro; Pastan, Ira et al. (2014) Keap1 inhibition attenuates glomerulosclerosis. Nephrol Dial Transplant 29:783-91
Bera, Tapan K; Onda, Masanori; Kreitman, Robert J et al. (2014) An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. Leuk Res :
Terrier, Benjamin; Nagata, Satoshi; Ise, Tomoko et al. (2014) CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Arthritis Rheumatol 66:433-43
Sakamoto, Kazuo; Ueno, Toshiharu; Kobayashi, Namiko et al. (2014) The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis. Am J Physiol Renal Physiol 306:F98-F104
Liu, Xiu-Fen; Xiang, Laiman; FitzGerald, David J et al. (2014) Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors. Mol Cancer Ther 13:82-9
Haso, Waleed; Lee, Daniel W; Shah, Nirali N et al. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121:1165-74

Showing the most recent 10 out of 25 publications